[O1] Oral Session 1　消化器1（上部消化管）
【E】

[O1-1] Second-line tislelizumab vs chemotherapy in advanced or metastatic ESCC: RATIONALE 302 Japanese subgroup

^○Hiroki Hara¹, Taroh Satoh², Takashi Kojima³, Satoru Motoyama⁴, Takahiro Tsushima⁵, Yu Sunakawa⁶, Morihito Okada⁷, Aiyang Tao⁸, Ningning Ding⁸, Ken Kato⁹ (1.Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan, 2.Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan, 3.Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, 4.Department of Esophageal Surgery, Akita University Hospital, Akita, Japan, 5.Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan, 6.Department of Clinical Oncology, St. Marianna University School of Medicine, Kanagawa, Japan, 7.Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan, 8.BeiGene Ltd, Zhongguancun Life Science Park, Beijing, China, 9.Department of Head and Neck Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan)